



Universiteit
Leiden
The Netherlands

The aging B cell landscape in atherosclerosis

Mol, J. de

Citation

Mol, J. de. (2025, December 11). *The aging B cell landscape in atherosclerosis*. Retrieved from <https://hdl.handle.net/1887/4285092>

Version: Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4285092>

Note: To cite this publication please use the final published version (if applicable).

REFERENCES

1. Tsao, C. W. et al. Heart Disease and Stroke Statistics-2023 Update: A Report From the American Heart Association. *Circulation* 147, E93–E621 (2023).
2. Johansson, A., Drake, I., Engström, G. & Acosta, S. Modifiable and Non-Modifiable Risk Factors for Atherothrombotic Ischemic Stroke among Subjects in the Malmö Diet and Cancer Study. *Nutrients* 13, (2021).
3. Libby, P. The changing landscape of atherosclerosis. *Nature* 2021 592:7855 592, 524–533 (2021).
4. Bhargava, S., de la Puente-Secades, S., Schurgers, L. & Jankowski, J. Lipids and lipoproteins in cardiovascular diseases: a classification. *Trends in Endocrinology & Metabolism* 33, 409–423 (2022).
5. Yoshida, H. & Kisugi, R. Mechanisms of LDL oxidation. *Clinica Chimica Acta* vol. 411 1875–1882 Preprint at <https://doi.org/10.1016/j.cca.2010.08.038> (2010).
6. Wolf, D. & Ley, K. Immunity and Inflammation in Atherosclerosis. *Circulation Research* vol. 124 315–327 Preprint at <https://doi.org/10.1161/CIRCRESAHA.118.313591> (2019).
7. Ait-Oufella, H. & Libby, P. Inflammation and Atherosclerosis: Prospects for Clinical Trials. *Arterioscler Thromb Vasc Biol* 44, 1899–1905 (2024).
8. Tsiatoulas, D., Diehl, C. J., Witztum, J. L. & Binder, C. J. B-cells and humoral immunity in atherosclerosis. *Circulation Research* vol. 114 1743–1756 Preprint at <https://doi.org/10.1161/CIRCRESAHA.113.301145> (2014).
9. Bentzon, J. F., Otsuka, F., Virmani, R. & Falk, E. Mechanisms of plaque formation and rupture. *Circ Res* 114, 1852–1866 (2014).
10. Santoro, A., Bientinesi, E. & Monti, D. Immunosenescence and inflammaging in the aging process: age-related diseases or longevity? *Ageing Res Rev* 71, (2021).
11. Min, H., Montecino-Rodriguez, E. & Dorshkind, K. Effects of Aging on the Common Lymphoid Progenitor to Pro-B-cell Transition. *The Journal of Immunology* 176, 1007–1012 (2006).
12. Keren, Z. et al. B-cell depletion reactivates B lymphopoiesis in the BM and rejuvenates the B lineage in aging. *Blood* 117, 3104–3112 (2011).
13. Tabibian-Keissar, H. et al. Aging affects B-cell antigen receptor repertoire diversity in primary and secondary lymphoid tissues. *Eur J Immunol* 46, 480–492 (2016).
14. Nickerson, K. M. et al. Age-associated B-cells are heterogeneous and dynamic drivers of autoimmunity in mice. *J Exp Med* 220, e20221346–e20221346 (2023).
15. Grievink, H. W. et al. Cardiovascular risk factors: The effects of ageing and smoking on the immune system, an observational clinical study. *Front Immunol* 13, 5391 (2022).
16. McDonald, K. G., Leach, M. R., Huang, C., Wang, C. & Newberry, R. D. Aging impacts isolated lymphoid follicle development and function. *Immunity and Ageing* 8, 1–12 (2011).
17. Fujiyoshi, K. et al. Incidence, factors, and clinical significance of cholesterol crystals in coronary plaque: An optical coherence tomography study. *Atherosclerosis* 283, 79–84 (2019).
18. Man, J. J., Beckman, J. A. & Jaffe, I. Z. Sex as a Biological Variable in Atherosclerosis. *Circ Res* 126, 1297–1319 (2020).
19. Liu, H. et al. Inflammatory Macrophage Interleukin-1 β Mediates High-Fat Diet-Induced Heart Failure With Preserved Ejection Fraction. *JACC Basic Transl Sci* 8, 174 (2022).
20. Katkenov, N. et al. Systematic Review on the Role of IL-6 and IL-1 β in Cardiovascular Diseases. *J Cardiovasc Dev Dis* 11, 206 (2024).
21. Patterson, M. T. et al. Trem2 promotes foamy macrophage lipid uptake and survival in atherosclerosis. *Nature Cardiovascular Research* 2023 2:11 2, 1015–1031 (2023).
22. Donado, C. A. et al. Granzyme K activates the entire complement cascade. *Nature* 2025 1–11 (2025) doi:10.1038/s41586-025-08713-9.
23. Braunersreuther, V. et al. Ccr5 but not Ccr1 deficiency reduces development of diet-induced atherosclerosis in mice. *Arterioscler Thromb Vasc Biol* 27, 373–379 (2007).
24. Lee, W.-W., Nam, K.-H., Terao, K., Akari, H. & Yoshikawa, Y. Age-related increase of peripheral CD4⁺ CD8⁺ double-positive T lymphocytes in cynomolgus monkeys: longitudinal study in relation to thymic involution. *Immunology* 109, 217–225 (2003).
25. Zoller, A. L. & Kersh, G. J. Estrogen induces thymic atrophy by eliminating early thymic progenitors and inhibiting proliferation of beta-selected thymocytes. *J Immunol* 176, 7371–7378 (2006).
26. Douna, H. et al. Bidirectional effects of IL-10⁺ regulatory B-cells in Ldlr^{-/-} mice. *Atherosclerosis* 280, 118–125 (2019).
27. Ransgnola, B. P., Pattarabanjird, T. & McNamara, C. A. Tipping the Scale: Atheroprotective IgM-Producing B-cells in Atherosclerosis. *Arterioscler Thromb Vasc Biol* 44, 1906–1915 (2024).
28. Wang, S. et al. IL-21 drives expansion and plasma cell differentiation of autoreactive CD11chiT-bet⁺ B-cells in SLE. *Nat Commun* 9, 1–14 (2018).
29. Grimaldi, C. M., Jeganathan, V. & Diamond, B. Hormonal regulation of B-cell development: 17 beta-estradiol impairs negative selection of high-affinity DNA-reactive B-cells at more than one developmental checkpoint. *J Immunol* 176, 2703–2710 (2006).
30. Jeganathan, V., Peeva, E. & Diamond, B. Hormonal milieu at time of B-cell activation controls duration of autoantibody response. *J Autoimmun* 53, 46–54 (2014).

31. Sarmiento, L., Svensson, J., Barchetta, I., Giwerzman, A. & Cilio, C. M. Copy number of the X-linked genes TLR7 and CD40L influences innate and adaptive immune responses. *Scand J Immunol* 90, (2019).
32. Krouwer, V. J. D., Hekking, L. H. P., Langelaar-Makkinje, M., Regan-Klapisz, E. & Post, J. A. Endothelial cell senescence is associated with disrupted cell-cell junctions and increased monolayer permeability. *Vasc Cell* 4, (2012).
33. Becker, L. et al. Age-dependent Shift in Macrophage Polarization Causes Inflammation Mediated Degeneration of Enteric Nervous System. *Gut* 67, 827 (2017).
34. Chen, J. et al. Aging Is Associated With Increased T-Cell Chemokine Expression in C57Bl/6 Mice. *The Journals of Gerontology: Series A* 58, B975–B983 (2003).
35. Mittelbrunn, M. & Kroemer, G. Hallmarks of T-cell aging. *Nature Immunology* vol. 22 687–698 Preprint at <https://doi.org/10.1038/s41590-021-00927-z> (2021).
36. Pattarabanjird, T. et al. Single-cell profiling of CD11c+ B-cells in atherosclerosis. *Front Immunol* 14, 1296668 (2023).
37. Masle-Farquhar, E. et al. Uncontrolled CD21low age-associated and B1 B-cell accumulation caused by failure of an EGR2/3 tolerance checkpoint. *Cell Rep* 38, (2022).
38. Knox, J. J. et al. T-bet-expressing B-cells promote atherosclerosis in apolipoprotein E-deficient mice. *J Immunol* (2025) doi:10.1093/JIMMUN/VKAE027.
39. Liu, S. et al. B-cell-intrinsic IFN- γ promotes excessive CD11c+ age-associated B-cell differentiation and compromised germinal center selection in lupus mice. *Cell Immunol* 405–406, (2024).
40. Khan, A. R. et al. PD-L1hi B-cells are critical regulators of humoral immunity. *Nat Commun* 6, (2015).
41. Wiley, C. D. & Campisi, J. The metabolic roots of senescence: mechanisms and opportunities for intervention. *Nature Metabolism* 2021 3:10 3, 1290–1301 (2021).
42. Peeters, R. & Jellusova, J. Lipid metabolism in B-cell biology. *Mol Oncol* 18, 1795–1813 (2024).
43. Frasca, D., Saada, Y. B., Garcia, D. & Friguet, B. Effects of cellular senescence on metabolic pathways in non-immune and immune cells. *Mech Ageing Dev* 194, 111428 (2021).
44. Li, J., Kim, S. G. & Blenis, J. Rapamycin: one drug, many effects. *Cell Metab* 19, 373–9 (2014).
45. Kasiske, B. L. et al. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. *American Journal of Transplantation* 8, 1384–1392 (2008).
46. Araki, K. et al. mTOR regulates memory CD8 T-cell differentiation. *Nature* 460, 108–112 (2009).
47. Petersone, L. et al. IL-21 shapes germinal center polarization via light zone B-cell selection and cyclin D3 upregulation. *Journal of Experimental Medicine* 220, (2023).
48. Matjusaitis, M., Chin, G., Samoski, E. A. & Stolzing, A. Biomarkers to identify and isolate senescent-cells. *Ageing Res Rev* 29, 1–12 (2016).
49. Hao, Y., O'Neill, P., Naradikion, M. S., Scholz, J. L. & Cancro, M. P. A B-cell subset uniquely responsive to innate stimuli accumulates in aged mice. *Blood* 118, 1294–1304 (2011).
50. Ghosn, E. E. B., Yang, Y., Tung, J., Herzenberg, L. A. & Herzenberg, L. A. CD11b expression distinguishes sequential stages of peritoneal B-1 development. *Proc Natl Acad Sci U S A* 105, 5195 (2008).
51. Williams, C. G., Lee, H. J., Asatsuma, T., Vento-Tormo, R. & Haque, A. An introduction to spatial transcriptomics for biomedical research. *Genome Med* 14, 1–18 (2022).
52. Mohanta, S. K. et al. Artery tertiary lymphoid organs contribute to innate and adaptive immune responses in advanced mouse atherosclerosis. *Circulation Research* vol. 114 1772–1787 Preprint at <https://doi.org/10.1161/CIRCRESAHA.114.301137> (2014).
53. Srikakulapu, P. et al. Artery tertiary lymphoid organs control multilayered territorialized atherosclerosis B-cell responses in Aged ApoE-/- mice. *Arterioscler Thromb Vasc Biol* 36, 1174–1185 (2016).
54. Wu, C. et al. Single-cell transcriptomics reveal potent extrafollicular B-cell response linked with granzyme K+ CD8 T-cell activation in lupus kidney. *Ann Rheum Dis* 0, 1–15 (2024).
55. Ma, S. et al. Spatial transcriptomic landscape unveils immunoglobulin-associated senescence as a hallmark of aging. *Cell* 187, 7025-7044.e34 (2024).
56. Zheng, B., Yang, Y., Chen, L., Wu, M. & Zhou, S. B-cell receptor repertoire sequencing: Deeper digging into the mechanisms and clinical aspects of immune-mediated diseases. *iScience* 25, 105002 (2022).
57. Viant, C., Escolano, A., Chen, S. T. & Nussenzweig, M. C. Sequencing, cloning, and antigen binding analysis of monoclonal antibodies isolated from single mouse B-cells. *STAR Protoc* 2, (2021).
58. Vukovic, J., Abazovic, D., Vucetic, D. & Medenica, S. CAR-engineered T-cell therapy as an emerging strategy for treating autoimmune diseases. *Front Med (Lausanne)* 11, 1447147 (2024).
59. Schett, G. et al. Advancements and challenges in CAR T-cell therapy in autoimmune diseases. *Nature Reviews Rheumatology* 2024 20:9 20, 531–544 (2024).
60. Bagni, G. et al. Epigenetics in autoimmune diseases: Unraveling the hidden regulators of immune dysregulation. *Autoimmun Rev* 24, 103784 (2025).
61. Xiao, F. et al. Epigenetic regulation of B-cells and its role in autoimmune pathogenesis. *Cell Mol Immunol* 19, 1215 (2022).
62. Hamilton, S. E. & Griffith, T. S. A wild microbiome improves mouse modeling of the human immune response. *Lab Animal* 2019 48:11 48, 337–338 (2019).
63. Ma, J. et al. Laboratory mice with a wild microbiota generate strong allergic immune responses. *Sci Immunol* 8, (2023).
64. Chen, J. et al. The development and improvement of immunodeficient mice and humanized immune system mouse models. *Front Immunol* 13, (2022).

65. Van der Veken, B., Roth, L., De Meyer, G. R. Y. & Martinet, W. Development of atherosclerotic plaques in a mouse model of pseudoxanthoma elasticum. *Acta Cardiol* 69, 687–692 (2014).
66. Van Der Donckt, C. et al. Elastin fragmentation in atherosclerotic mice leads to intraplaque neovascularization, plaque rupture, myocardial infarction, stroke, and sudden death. *Eur Heart J* 36, 1049–1058 (2015).
67. Maringanti, R. et al. Atherosclerosis on a Chip: A 3-Dimensional Microfluidic Model of Early Arterial Events in Human Plaques. *Arterioscler Thromb Vasc Biol* (2024) doi:10.1161/ATVBAHA.124.321332/SUPPL_FILE/ATVB_ATVB-2024-321332D_SUPP1.PDF.
68. RITA-MI - Health Research Authority. <https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/rita-mi/>.
69. RITA-MI 2 - Health Research Authority. <https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/rita-mi-2/>.
70. Vellasamy, D. M. et al. Targeting Immune Senescence in Atherosclerosis. *Int J Mol Sci* 23, (2022).
71. Huang, W., Hickson, L. T. J., Eirin, A., Kirkland, J. L. & Lerman, L. O. Cellular senescence: the good, the bad and the unknown. *Nature Reviews Nephrology* 2022 18:10 18, 611–627 (2022).

SCIENTIFIC PUBLICATIONS

Mulholland M., Chalou A., Andersson S., Depuydt M., Yu Y., Lin S., Tallbäck K., Ericsson A., Jakobsson G., **Mol J. de**, Lichtman A.H., Foks A.C., Schiopu A., Björkbacka H., Slütter B., Gisterå A., Engelbertsen D. Progenitor exhausted PD1⁺ T-cells are cellular targets of immune checkpoint inhibition in atherosclerosis. *Nat Cardiovasc Res*. Accepted for publication (2025).

Mol J. de, Smit V., Bernabé Kleijn M.N.A., Santbrink P.J. van, Bot I., Foks A.C. Immunosenescence accelerates atherosclerosis development in AAV-PCSK9 mouse model. *GeroScience*. In press (2025).

Schaftenaar F.H., Dam A.D. van, Bruin G. de, Depuydt M.A.C., **Mol J. de**, Amersfoort J., Douna H., Meijer M., Kröner M.J., Santbrink P.J. van, Bernabé Kleijn M.N.A., Puijvelde G.H.M. van, Florea B.I., Slütter B., Foks A.C., Bot I., Rensen P.C.N., Kuiper J. Immunoproteasomal Inhibition with ONX-0914 Attenuates Atherosclerosis and Reduces White Adipose Tissue Mass and Metabolic Syndrome in Mice, *Arteriosclerosis, Thrombosis, and Vascular Biology* 44(6):1346-1364 (2024).

Smit V., **Mol J. de**, Bernabé Kleijn M.N.A., Depuydt M.A.C., Winther M.P.J. de, Bot I., Kuiper J., Foks A.C. Sexual dimorphism in atherosclerotic plaques of aged *Ldlr*^{-/-} mice. *Immunity & Ageing* 21 (1):27 (2024).

Smit V., **Mol J. de**, Schaftenaar F.H., Depuydt M.A.C., Postel R.J., Smeets D., Verheijen F.W.M., Bogers L., Duijn J. van, Verwilligen R.A.F., Grievink H.W., Bernabé Kleijn M.N.A., Ingen E. van, Jong M.J.M. de, Goncalves L., Peeters J.A.H.M., Smeets H.J., Wezel A., Polansky J.K., Winther M.P.J. de, Binder C.J., Tsiantoulas D., Bot I., Kuiper J., Foks A.C. Single-cell profiling reveals age-associated immunity in atherosclerosis. *Cardiovascular Research* 119(15):2508-2521 (2023).

Depuydt M.A.C., Schaftenaar F.H., Prange K.H.M., Boltjes A., Hemme E., Delfos L., **Mol J. de**, Jong M.J.M. de, Bernabé Kleijn M.N.A., Peeters A.H.M., Goncalves L., Wezel A., Smeets H.J., Borst G.J. de, Foks A.C., Pasterkamp G., Winther M.P.J. de, Kuiper J., Bot I., Slütter B. Single-cell T-cell receptor sequencing of paired human atherosclerotic plaques and blood reveals autoimmune-like features of expanded effector T-cells. *Nature Cardiovascular Research* 2:112-125 (2023).

Mol J. de, Douna H., Amersfoort J., Schaftenaar F.H., Kiss M.G., Suur B.E., Kroner M.J., Binder C.J., Bot I., van Puijvelde G.H.M., Kuiper J., Foks A.C. IFN γ -stimulated B-cells inhibit T follicular helper cells and protect against atherosclerosis. *Frontiers in Cardiovascular Medicine* 9:781436 (2022).

Mol J. de, Kuiper J., Tsiantoulas D., Foks A.C. The dynamics of B-cell aging in health and disease. *Frontiers in Immunology* 12:73356 (2021).

CURRICULUM VITAE

Jill de Mol werd geboren op 29 september 1997 te Voorburg. In 2015 behaalde zij haar atheneumdiploma aan het Zandvlietcollege in Den Haag. Datzelfde jaar begon zij aan de bacheloropleiding Bio-Farmaceutische Wetenschappen aan de Universiteit Leiden. Daar liep zij haar eerste stage onder begeleiding van drs. Olga Snip in de groep van prof. dr. Miranda van Eck. In 2018 behaalde Jill haar Bachelor of Science diploma, waarna ze begon aan de masteropleiding Bio-Pharmaceutical Sciences aan de Universiteit Leiden. Tijdens haar eerste wetenschappelijke masterstage aan de divisie BioTherapeutics van het LACDR deed Jill onderzoek naar het therapeutisch potentieel van anionische rapamycine liposomen tegen de behandeling van atherosclerose onder begeleiding van dr. Naomi Benne en dr. Bram Slütter. Jill heeft haar tweede wetenschappelijke stage uitgevoerd onder begeleiding van dr. Eva Kritikou en prof. dr. Andrew Lichtman aan Harvard Medical School in Boston (VS), waar ze onderzoek deed naar de bijwerkingen van het remmen van immuuncheckpoints op atherosclerose ontwikkeling. In 2020 behaalde zij haar Master of Science diploma, *cum laude*.

Van september 2020 tot en met december 2024 was Jill werkzaam als promovenda binnen de Aging & Immunity groep bij de divisie BioTherapeutics van het LACDR onder begeleiding van dr. Amanda Foks, dr. Bram Slütter en prof. dr. Johan Kuiper, op het internationale ERA-CVD project ‘The role of B-cell immunity in accelerated atherosclerosis (B-eat-ATHERO)’ dat gefinancierd werd door de Hartstichting. Voor het onderzoek uit dit proefschrift ontving Jill een beste posterpresentatie prijs bij de 6e Graz Expert Meeting (2024) betreffende single-cell RNA sequencing technologieën in het cardiovasculaire veld. Daarnaast ontving zij een prijs voor haar presentatie bij de Dutch Atherosclerosis Society (DAS) meeting in 2024. Sinds december 2024 werkt Jill als post-doctoraal onderzoeker bij de divisie BioTherapeutics van het LACDR onder leiding van dr. Amanda Foks om het onderzoek naar verouderde B-cellen in atherosclerose en hartinfarcten voort te zetten binnen het ERA4Health MARGINALIZE-MI consortium.

PHD PORTFOLIO

Courses

2020	Scientific conduct (Universiteit Leiden)
2020	Animal handling course (Universiteit Leiden)
2021	LACDR PhD introductory course (Universiteit Leiden)
2021	Data management course (Universiteit Leiden)
2021	Communication in science (Universiteit Leiden)
2021	Vascular biology and pathology (Hartstichting)
2022	Teaching and supervision (Universiteit Leiden)
2022	ULLA summerschool (Uppsala University)
2023	Venture academy (PLNT Leiden)
2025	Career Café CV & Motivation Letter (Universiteit Leiden)

Presentations

2021	LACDR Spring Symposium – poster presentation
2021	NVVI (Dutch Society for Immunology) Annual Meeting – oral presentation
2021	Rembrandt Symposium – poster presentation
2022	LACDR Spring Symposium – poster presentation
2022	Frontiers in Cardiovascular Biomedicine – poster presentation
2022	DUSRA (Dutch Society for Research on Aging) – oral presentation
2022	ERA CVD Symposium – poster presentation
2022	Rembrandt Symposium – oral presentation
2022	NVVI (Dutch Society for Immunology) Annual Meeting – poster presentation
2023	LACDR Spring Symposium – poster presentation
2023	Dutch Atherosclerosis Society – poster presentation
2023	European Atherosclerosis Society – short oral presentation
2023	NVVI (Dutch Society for Immunology) Annual Meeting – poster presentation
2024	Cardiovasculair NL-BE_DE young PI annual meeting – oral presentation
2024	Danish Cardiovascular Academy – oral presentation
2024	Frontiers in Cardiovascular Biomedicine – poster presentation
2024	LACDR Spring Symposium – oral presentation
2024	Dutch Atherosclerosis Society – oral presentation (award)
2024	European Atherosclerosis Society – poster presentation
2024	Dutch CardioVascular Alliance Symposium – oral presentation
2024	6th Graz Expert Meeting on Single-cell Technologies – poster presentation (award)
2025	Leiden CardioVascularMedicine meeting – oral presentation
2025	Atherosclerosis Gordon Research Seminar – poster presentation
2025	Atherosclerosis Gordon Research Conference – poster presentation